Cargando…
(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
PURPOSE: (18)F-DCFPyL prostate-specific membrane antigen (PSMA) PET/CT is commonly applied to locate lesions of prostate cancer (PCa), but its diagnostic function of quantitative parameters is ignored. Our study evaluates the parameters of intraprostatic PSMA uptake in patients newly diagnosed with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850639/ https://www.ncbi.nlm.nih.gov/pubmed/35186741 http://dx.doi.org/10.3389/fonc.2022.800904 |
_version_ | 1784652643032891392 |
---|---|
author | Zhou, Shuoming Liu, Tiantian Zhu, Ziqiang Zhang, Lin Qian, Subo Fu, Hongliang Cao, Qifeng Kang, Jian |
author_facet | Zhou, Shuoming Liu, Tiantian Zhu, Ziqiang Zhang, Lin Qian, Subo Fu, Hongliang Cao, Qifeng Kang, Jian |
author_sort | Zhou, Shuoming |
collection | PubMed |
description | PURPOSE: (18)F-DCFPyL prostate-specific membrane antigen (PSMA) PET/CT is commonly applied to locate lesions of prostate cancer (PCa), but its diagnostic function of quantitative parameters is ignored. Our study evaluates the parameters of intraprostatic PSMA uptake in patients newly diagnosed with PCa and explores their predictive value in risk classification, which is similar to D’Amico criteria. MATERIALS AND METHODS: We quantified the maximal standardized uptake value (SUVmax), mean SUV (SUVmean), total lesion (TL)-PSMA, prostate/muscle (P/M) ratio of the primary tumor, and PSMA-derived tumor volume (PSMA-TV) from 62 patients with histologically proven PCa. Patients newly diagnosed with PCa were allocated into risk groups (at low, intermediate, and high risk, respectively) in accordance with D’Amico criteria. Afterwards, the five parameters mentioned above among three different risk groups were compared, and their predictive values in the risk classification of PCa were explored. RESULTS: Significantly decreased levels of SUVmax, SUVmean, TL-PSMA, and P/M ratio were observed in the risk groups of low or intermediate or both, compared with the high-risk group. However, only the P/M ratio significantly elevated in patients with intermediate risk [mean ± SD (median): 46.58 ± 9.74 (45.27), P = 0.042] or high risk [98.95 ± 38.83 (97.52), P < 0.001], compared with low-risk patients [12.33 ± 5.93 (9.81)]. When P/M ratio was used to distinguish between low-risk and intermediate-risk patients, its c-statistics was 0.660. On the other hand, when distinguishing between intermediate-risk and high-risk groups, the c-statistics of P/M ratio was 0.667. Finally, when P/M ratio was used to distinguish between low-risk and high-risk patients, the c-statistics was 0.969. P/M ratio had a positive correlation with prostate-specific antigen in all enrolled PCa patients. CONCLUSION: The quantitative parameters of (18)F-DCFPyL PET/CT, including SUVmax, SUVmean, and P/M ratio, might assist in distinguishing low-risk or intermediate-risk groups from the high-risk group. Of these parameters, P/M ratio appears to be the better promising parameter for risk classification of prostate cancer than SUVmax. |
format | Online Article Text |
id | pubmed-8850639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88506392022-02-18 (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer Zhou, Shuoming Liu, Tiantian Zhu, Ziqiang Zhang, Lin Qian, Subo Fu, Hongliang Cao, Qifeng Kang, Jian Front Oncol Oncology PURPOSE: (18)F-DCFPyL prostate-specific membrane antigen (PSMA) PET/CT is commonly applied to locate lesions of prostate cancer (PCa), but its diagnostic function of quantitative parameters is ignored. Our study evaluates the parameters of intraprostatic PSMA uptake in patients newly diagnosed with PCa and explores their predictive value in risk classification, which is similar to D’Amico criteria. MATERIALS AND METHODS: We quantified the maximal standardized uptake value (SUVmax), mean SUV (SUVmean), total lesion (TL)-PSMA, prostate/muscle (P/M) ratio of the primary tumor, and PSMA-derived tumor volume (PSMA-TV) from 62 patients with histologically proven PCa. Patients newly diagnosed with PCa were allocated into risk groups (at low, intermediate, and high risk, respectively) in accordance with D’Amico criteria. Afterwards, the five parameters mentioned above among three different risk groups were compared, and their predictive values in the risk classification of PCa were explored. RESULTS: Significantly decreased levels of SUVmax, SUVmean, TL-PSMA, and P/M ratio were observed in the risk groups of low or intermediate or both, compared with the high-risk group. However, only the P/M ratio significantly elevated in patients with intermediate risk [mean ± SD (median): 46.58 ± 9.74 (45.27), P = 0.042] or high risk [98.95 ± 38.83 (97.52), P < 0.001], compared with low-risk patients [12.33 ± 5.93 (9.81)]. When P/M ratio was used to distinguish between low-risk and intermediate-risk patients, its c-statistics was 0.660. On the other hand, when distinguishing between intermediate-risk and high-risk groups, the c-statistics of P/M ratio was 0.667. Finally, when P/M ratio was used to distinguish between low-risk and high-risk patients, the c-statistics was 0.969. P/M ratio had a positive correlation with prostate-specific antigen in all enrolled PCa patients. CONCLUSION: The quantitative parameters of (18)F-DCFPyL PET/CT, including SUVmax, SUVmean, and P/M ratio, might assist in distinguishing low-risk or intermediate-risk groups from the high-risk group. Of these parameters, P/M ratio appears to be the better promising parameter for risk classification of prostate cancer than SUVmax. Frontiers Media S.A. 2022-02-03 /pmc/articles/PMC8850639/ /pubmed/35186741 http://dx.doi.org/10.3389/fonc.2022.800904 Text en Copyright © 2022 Zhou, Liu, Zhu, Zhang, Qian, Fu, Cao and Kang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhou, Shuoming Liu, Tiantian Zhu, Ziqiang Zhang, Lin Qian, Subo Fu, Hongliang Cao, Qifeng Kang, Jian (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer |
title | (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer |
title_full | (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer |
title_fullStr | (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer |
title_full_unstemmed | (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer |
title_short | (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer |
title_sort | (18)f-dcfpyl pet/ct in newly diagnosed prostate cancer: diagnostic value of intraprostatic psma uptake in risk classification of prostate cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850639/ https://www.ncbi.nlm.nih.gov/pubmed/35186741 http://dx.doi.org/10.3389/fonc.2022.800904 |
work_keys_str_mv | AT zhoushuoming 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer AT liutiantian 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer AT zhuziqiang 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer AT zhanglin 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer AT qiansubo 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer AT fuhongliang 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer AT caoqifeng 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer AT kangjian 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer |